Heluo Xintu Completes New Round of Financing to Advance iPSC-Derived Platelet Therapeutics

October 15th, Renerval Therapeutics announced the completion of a new round of financing. The funds raised will mainly be used to promote the optimization of Renerval Therapeutics' clinical-grade regenerative platelet cell production process and the launch of clinical trials, as well as to accelerate the research and development of other innovative products and pipelines.

Renerval Therapeutics was founded in 2021. The founding team is led by returning scholars from the Massachusetts Institute of Technology and the University of Cambridge. It is a high-tech innovative enterprise aimed at iPSC directed differentiation, gene editing, large-scale cell product preparation, and cell therapy technology development.